These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression. Lee JJA; Saito T; Duddy W; Takeda S; Yokota T Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539 [TBL] [Abstract][Full Text] [Related]
3. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy. Wilton SD; Fletcher S Curr Pharm Des; 2010; 16(8):988-1001. PubMed ID: 20041827 [TBL] [Abstract][Full Text] [Related]
4. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998 [TBL] [Abstract][Full Text] [Related]
5. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient. Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540 [TBL] [Abstract][Full Text] [Related]
6. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Echigoya Y; Yokota T Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394 [TBL] [Abstract][Full Text] [Related]
7. Exon skipping and Duchenne muscular dystrophy: hope, hype and how feasible? Wilton SD; Fletcher S Neurol India; 2008; 56(3):254-62. PubMed ID: 18974551 [TBL] [Abstract][Full Text] [Related]
8. Contributions of Japanese patients to development of antisense therapy for DMD. Matsuo M; Takeshima Y; Nishio H Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594 [TBL] [Abstract][Full Text] [Related]
9. Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies. Toh ZY; Thandar Aung-Htut M; Pinniger G; Adams AM; Krishnaswarmy S; Wong BL; Fletcher S; Wilton SD PLoS One; 2016; 11(1):e0145620. PubMed ID: 26745801 [TBL] [Abstract][Full Text] [Related]
10. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660 [TBL] [Abstract][Full Text] [Related]
11. [Mutation-specific treatments for Duchenne muscular dystrophy]. Matsuo M; Takeshima Y Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880 [TBL] [Abstract][Full Text] [Related]
12. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice. Hiller M; Spitali P; Datson N; Aartsma-Rus A Methods Mol Biol; 2018; 1828():249-262. PubMed ID: 30171546 [TBL] [Abstract][Full Text] [Related]
13. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800 [TBL] [Abstract][Full Text] [Related]